Longevity & AgingGLP-1 Drugs Cut Heart Failure and Stroke Risk in High-Stakes Heart Procedures
GLP-1 receptor agonist drugs, best known for weight loss and diabetes, are showing cardiovascular benefits in patients undergoing two high-risk heart procedures. In one study, tirzepatide reduced heart failure events by roughly 32% and kidney injury by 37% in patients who had transcatheter aortic valve replacement (TAVR). A second study found GLP-1 drug users undergoing carotid artery stenting had significantly fewer major adverse cardiovascular events, including heart attack, stroke, and death, at one year. Both studies were observational and presented at a major cardiology conference. Researchers suggest these drugs may address underlying metabolic dysfunction that persists after structural heart procedures, pointing to a new role for GLP-1 therapies beyond weight and blood sugar management.
